Skip to main content
Signal8

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

$INCYPress releaseJul 6, 2026, 8:39 AM ETRead the release

Incyte completed its acquisition of Vega Therapeutics from Star Therapeutics for $1.25 billion upfront to expand its hematology portfolio. The deal adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease which holds FDA Breakthrough Therapy and orphan drug designations.

Key figures

Drug Name
VGA039
Deal Value Usd
1250000000
Phase Of Trial
Phase 3
Trial id
NCT07115004
Milestone payments usd
750000000
Vwd patients diagnosed us
135000

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.